Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Shares in Novavax almost doubled ...
Sanofi on Friday said it had reached a deal worth up to $1.2 billion to sell Novavax’s Covid shot as well as to try to ...
Novavax shares (NVAX) surged after the vaccine maker said it had struck a licensing deal worth up to $1.4 billion with Sanofi ...
Shah Capital, a top shareholder of Novavax (NASDAQ:NVAX), has withdrawn its proxy campaign against the company days after the ...
Gaithersburg's Novavax is getting a big cash infusion after signing a multibillion-dollar deal with French pharmaceutical ...
The deal also entitles Novavax to an upfront ... as well as royalties. Sanofi, one of the world's largest vaccine makers, will gain a license to co-sell Novavax's vaccine in most countries and ...
Hedge fund Shah Capital said on Monday it would withdraw its campaign against the re-election of three directors on Novavax's ...
Novavax shares jumped 50% on Monday following its recent licensing deal with Sanofi, as meme stocks are making a 2021-style ...
Novavax (NASDAQ:NVAX) shares hit a 52-week high on Friday as the COVID-19 vaccine maker removed its going-concern notice with ...
Sanofi will also have a non-exclusive license to use Novavax's Matrix-M adjuvant in other vaccine products. Novavax will ...
Novavax on Friday said it had struck a licensing deal worth at least $1.2 billion with Sanofi, opens new tab for its COVID-19 vaccine in exchange for a stake that valued the U.S. biotech firm at ...